Markets:

Overview

News

Currencies

International

Treasuries

Vistagen Therapeutics, Inc. - Common Stock (NQ:VTGN)

0.8833 -3.4767 (-79.74%)

Streaming Delayed Price Updated: 1:29 PM EST, Dec 17, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Vistagen Therapeutics, Inc. - Common Stock

< Previous 1 2

...

7 8 9 10 11 12 13 14 Next >

VistaGen Therapeutics Reports First Quarter Financial Results and Provides Corporate Update

August 11, 2022

From VistaGen Therapeutics, Inc.

Via Business Wire

Earnings Scheduled For August 11, 2022 ↗

August 11, 2022

Companies Reporting Before The Bell • Magic Software (NASDAQ:MGIC) is projected to report quarterly earnings at $0.27 per share on revenue of $131.70 million.

Via Benzinga

InvestorNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) to Host Conference Call to Discuss FY 2023 Q1 Financial Results

August 09, 2022

Via Investor Brand Network

VistaGen Therapeutics to Report Fiscal Year 2023 First Quarter Financial Results on August 11, 2022

August 09, 2022

From VistaGen

Via Business Wire

VistaGen Says Data From Late-Stage Anxiety Study 'Not Consistent' With Prior Positive Phase 2 Study ↗

July 22, 2022

Via Benzinga

Vistagen Therapeutics Shares Are Falling Sharply: Here's Why ↗

July 26, 2022

Vistagen Therapeutics Inc (NASDAQ: VTGN) shares are trading lower by 7.57% to $0.16 Tuesday morning after Maxim Group downgraded the stock from Buy to Hold. What Else?

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For July 26, 2022 ↗

July 26, 2022

Upgrades

Via Benzinga

12 Health Care Stocks Moving In Monday's After-Market Session ↗

July 25, 2022

Gainers

Via Benzinga

Recap Of Friday's Biotech Catalysts - End Of The Day Summary ↗

July 22, 2022

Via Benzinga

Why Energy Stocks Traded Higher; Here Are 61 Biggest Movers From Yesterday ↗

July 26, 2022

Gainers GeoVax Labs, Inc. (NASDAQ: GOVX) jumped 150.4% to close at $1.59 on Monday after declining 8% on Friday.

Via Benzinga

Dow Dips More Than 200 Points; Crude Oil Moves Lower ↗

July 22, 2022

U.S. stocks traded lower toward the end of trading, with the Dow Jones dropping more than 200 points on Friday.

Via Benzinga

This Technology Stock Surged 235%; Here Are 77 Biggest Movers From Friday ↗

July 25, 2022

Gainers

Via Benzinga

Stocks That Hit 52-Week Lows On Friday ↗

July 22, 2022

During Friday's session, 61 companies made new 52-week lows.

Via Benzinga

12 Health Care Stocks Moving In Friday's Intraday Session ↗

July 22, 2022

Via Benzinga

Why Is Pagaya Technologies (PGY) Stock Soaring 94% Today? ↗

July 22, 2022

Pagaya Technologies (PGY) stock is rocketing higher on Friday despite a lack of news from the financial tech company today.

Via InvestorPlace

Nasdaq Drops Around 200 Points; Hanger Shares Spike Higher ↗

July 22, 2022

U.S. stocks traded lower midway through trading, with the Nasdaq Composite dropping around 200 points on Friday.

Via Benzinga

VistaGen Therapeutics (VTGN) Stock Plunges on Disappointing Clinical Data ↗

July 22, 2022

VistaGen Therapeutics (VTGN) stock is falling hard on Friday after the company reported poor results from a Phase 3 study.

Via InvestorPlace

InvestorNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) Announces Topline Results from PALISADE-1 Phase 3 Clinical Trial for PH94B

July 22, 2022

Via Investor Brand Network

This Consumer Defensive Stock Is Trading Higher By Around 49%, Here Are 46 Stocks Moving In Friday's Mid-Day Session ↗

July 22, 2022

Gainers Pagaya Technologies Ltd. (NASDAQ: PGY) shares gained 93% to $10.32. Pagaya Technologies is expected to announce its Q2 earnings on August 16, 2022.

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For July 22, 2022 ↗

July 22, 2022

Upgrades

Via Benzinga

Daily Biotech Pulse: VistaGen's Anxiety Study Fails, Silverback To Merge With Firm Developing EpiPen Alternative, Setback For Liminal's Lead Asset ↗

July 22, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

VistaGen Announces Topline Results from PALISADE-1 Phase 3 Clinical Trial for Investigational Drug PH94B

July 22, 2022

From VistaGen Therapeutics, Inc.

Via Business Wire

Stocks That Hit 52-Week Lows On Tuesday ↗

July 19, 2022

Tuesday saw 37 companies set new 52-week lows.

Via Benzinga

Stocks That Hit 52-Week Lows On Friday ↗

July 15, 2022

On Friday, 137 stocks made new 52-week lows.

Via Benzinga

InvestorNewsBreaks — VistaGen Therapeutics Inc. (NASDAQ: VTGN) to Participate at 2022 Concordia Americas Summit; CEO and US Surgeon General to Discuss Mental Health Crisis

July 12, 2022

Via Investor Brand Network

VistaGen CEO Joins U.S. Surgeon General to Discuss Mental Health Crisis in America at the 2022 Concordia Americas Summit

July 12, 2022

From VistaGen Therapeutics, Inc.

Via Business Wire

InvestorNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) to Participate at William Blair Biotech Focus Conference 2022

July 07, 2022

Via Investor Brand Network

VistaGen to Participate at William Blair Biotech Focus Conference 2022

July 07, 2022

From VistaGen Therapeutics, Inc.

Via Business Wire

Stocks That Hit 52-Week Lows On Tuesday ↗

July 05, 2022

During Tuesday's session, 539 stocks hit new 52-week lows.

Via Benzinga

Looking Into VistaGen Therapeutics's Return On Capital Employed ↗

June 28, 2022

Benzinga Pro data, VistaGen Therapeutics (NASDAQ:VTGN) reported Q4 sales of $38.90 thousand. Earnings fell to a loss of $16.69 million, resulting in a 58.41% decrease from last quarter.

Via Benzinga

< Previous 1 2

...

7 8 9 10 11 12 13 14 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Vistagen Therapeutics, Inc. - Common Stock (NQ:VTGN)

All News about Vistagen Therapeutics, Inc. - Common Stock

Starting at $3.75/week.

Subscribe Today